Baindu L. Bayon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Baindu L. Bayon has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Debomoy K. Lahiri
Departments of Psychiatry and Medical & Molecular Genetics Indiana University School of Medicine Indianapolis IN USA
6 shared publicationsNipun Chopra
Departments of Psychiatry and Medical & Molecular Genetics Indiana University School of Medicine Indianapolis IN USA
4 shared publications- Bryan Maloney
Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
3 shared publications - Debomoy K. Lahiri
Department of Psychiatry Laboratory of Molecular Neurogenetics Indiana University School of Medicine Indianapolis Indiana USA
3 shared publications Balmiki Ray
Indiana University School of Medicine, Indianapolis, Indiana
2 shared publications- Craig A. Erickson
Division of Child and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
2 shared publications
Latest Publications
- 28 September 2022
- Published by Wiley in Journal of Engineering Education
- Vol. 111 (4) , 740-746
The climate is changing. Engineering education needs to change as well
- 28 September 2022
- Published by Wiley in Journal of Engineering Education
- Vol. 111 (4) , 740-746
The climate is changing. Engineering education needs to change as well
- 1 September 2018
- Published by Elsevier in NeuroToxicology
- Vol. 68, 126-132
Latent consequences of early-life lead (Pb) exposure and the future: Addressing the Pb crisis
- 1 September 2018
- Published by Elsevier in NeuroToxicology
- Vol. 68, 126-132
Latent consequences of early-life lead (Pb) exposure and the future: Addressing the Pb crisis
- 1 July 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (7S_Part_26)
[O4–06–01]: SP1‐MODULATING COMPOUNDS AS A NOVEL DRUG TARGET FOR ALZHEIMER'S DISEASE (AD)
- 1 July 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (7S_Part_26)
[O4–06–01]: SP1‐MODULATING COMPOUNDS AS A NOVEL DRUG TARGET FOR ALZHEIMER'S DISEASE (AD)
- 1 July 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (7S_Part_26)
[P4–030]: ROLE OF SP1 AND OTHER TRANSCRIPTION FACTORS (TFS) IN ALZHEIMER's DISEASE (AD)
- 1 July 2017
- Published by Wiley in Alzheimer's & Dementia
- Vol. 13 (7S_Part_26)
[P4–030]: ROLE OF SP1 AND OTHER TRANSCRIPTION FACTORS (TFS) IN ALZHEIMER's DISEASE (AD)
- 1 January 2017
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 84, 153-160
Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism
- 1 January 2017
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 84, 153-160
Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism
- Open Access
- 20 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0160314
Novel Nuclear Factor-KappaB Targeting Peptide Suppresses β-Amyloid Induced Inflammatory and Apoptotic Responses in Neuronal Cells
In the central nervous system (CNS), activation of the transcription factor nuclear factor-kappa B (NF-κβ) is associated with both neuronal survival and increased vulnerability to apoptosis. The mechanisms underlying these dichotomous effects are attributed to the composition of NF-κΒ dimers. In Alzheimer’s disease (AD), β-amyloid (Aβ) and other aggregates upregulate activation of p65:p50 dimers in CNS cells and enhance transactivation of pathological mediators that cause neuroinflammation and neurodegeneration. Hence selective targeting of activated p65 is an attractive therapeutic strategy for AD. Here we report the design, structural and functional characterization of peptide analogs of a p65 interacting protein, the glucocorticoid induced leucine zipper (GILZ). By virtue of binding the transactivation domain of p65 exposed after release from the inhibitory IκΒ proteins in activated cells, the GILZ analogs can act as highly selective inhibitors of activated p65 with minimal potential for off-target effects.
- 20 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0160314
Open AccessNovel Nuclear Factor-KappaB Targeting Peptide Suppresses β-Amyloid Induced Inflammatory and Apoptotic Responses in Neuronal Cells
In the central nervous system (CNS), activation of the transcription factor nuclear factor-kappa B (NF-κβ) is associated with both neuronal survival and increased vulnerability to apoptosis. The mechanisms underlying these dichotomous effects are attributed to the composition of NF-κΒ dimers. In Alzheimer’s disease (AD), β-amyloid (Aβ) and other aggregates upregulate activation of p65:p50 dimers in CNS cells and enhance transactivation of pathological mediators that cause neuroinflammation and neurodegeneration. Hence selective targeting of activated p65 is an attractive therapeutic strategy for AD. Here we report the design, structural and functional characterization of peptide analogs of a p65 interacting protein, the glucocorticoid induced leucine zipper (GILZ). By virtue of binding the transactivation domain of p65 exposed after release from the inhibitory IκΒ proteins in activated cells, the GILZ analogs can act as highly selective inhibitors of activated p65 with minimal potential for off-target effects.
- 21 June 2016
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (9) , 2334-2337
Analysis of peripheral amyloid precursor protein in Angelman Syndrome
Angelman Syndrome is a rare neurodevelopmental disorder associated with significant developmental and communication delays, high risk for epilepsy, motor dysfunction, and a characteristic behavioral profile. While Angelman Syndrome is known to be associated with the loss of maternal expression of the ubiquitin‐protein ligase E3A gene, the molecular sequelae of this loss remain to be fully understood. Amyloid precursor protein (APP) is involved in neuronal development and APP dysregulation has been implicated in the pathophysiology of other developmental disorders including fragile X syndrome and idiopathic autism. APP dysregulation has been noted in preclinical model of chromosome 15q13 duplication, a disorder whose genetic abnormality results in duplication of the region that is epigenetically silenced in Angelman Syndrome. In this duplication model, APP levels have been shown to be significantly reduced leading to the hypothesis that enhanced ubiquitin‐protein ligase E3A expression may be associated with this phenomena. We tested the hypothesis that ubiquitin‐protein ligase E3A regulates APP protein levels by comparing peripheral APP and APP derivative levels in humans with Angelman Syndrome to those with neurotypical development. We report that APP total, APP alpha (sAPPα) and A Beta 40 and 42 are elevated in the plasma of humans with Angelman Syndrome compared to neurotypical matched human samples. Additionally, we found that elevations in APP total and sAPPα correlated positively with peripheral brain derived neurotrophic factor levels previously reported in this same patient cohort. Our pilot report on APP protein levels in Angelman Syndrome warrants additional exploration and may provide a molecular target of treatment for the disorder.
- 21 June 2016
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (9) , 2334-2337
Analysis of peripheral amyloid precursor protein in Angelman Syndrome
Angelman Syndrome is a rare neurodevelopmental disorder associated with significant developmental and communication delays, high risk for epilepsy, motor dysfunction, and a characteristic behavioral profile. While Angelman Syndrome is known to be associated with the loss of maternal expression of the ubiquitin‐protein ligase E3A gene, the molecular sequelae of this loss remain to be fully understood. Amyloid precursor protein (APP) is involved in neuronal development and APP dysregulation has been implicated in the pathophysiology of other developmental disorders including fragile X syndrome and idiopathic autism. APP dysregulation has been noted in preclinical model of chromosome 15q13 duplication, a disorder whose genetic abnormality results in duplication of the region that is epigenetically silenced in Angelman Syndrome. In this duplication model, APP levels have been shown to be significantly reduced leading to the hypothesis that enhanced ubiquitin‐protein ligase E3A expression may be associated with this phenomena. We tested the hypothesis that ubiquitin‐protein ligase E3A regulates APP protein levels by comparing peripheral APP and APP derivative levels in humans with Angelman Syndrome to those with neurotypical development. We report that APP total, APP alpha (sAPPα) and A Beta 40 and 42 are elevated in the plasma of humans with Angelman Syndrome compared to neurotypical matched human samples. Additionally, we found that elevations in APP total and sAPPα correlated positively with peripheral brain derived neurotrophic factor levels previously reported in this same patient cohort. Our pilot report on APP protein levels in Angelman Syndrome warrants additional exploration and may provide a molecular target of treatment for the disorder.
- 7 March 2016
- Published by Taylor & Francis in Epigenomics
- Vol. 8 (3) , 373-387
Transgenerational Latent Early-Life Associated Regulation Unites Environment and Genetics Across Generations
The origin of idiopathic diseases is still poorly understood. The latent early-life associated regulation (LEARn) model unites environmental exposures and gene expression while providing a mechanistic underpinning for later-occurring disorders. We propose that this process can occur across generations via transgenerational LEARn (tLEARn). In tLEARn, each person is a ‘unit’ accumulating preclinical or subclinical ‘hits’ as in the original LEARn model. These changes can then be epigenomically passed along to offspring. Transgenerational accumulation of ‘hits’ determines a sporadic disease state. Few significant transgenerational hits would accompany conception or gestation of most people, but these may suffice to ‘prime’ someone to respond to later-life hits. Hits need not produce symptoms or microphenotypes to have a transgenerational effect. Testing tLEARn requires longitudinal approaches. A recently proposed longitudinal epigenome/envirome-wide association study would unite genetic sequence, epigenomic m...
- 7 March 2016
- Published by Taylor & Francis in Epigenomics
- Vol. 8 (3) , 373-387
Transgenerational Latent Early-Life Associated Regulation Unites Environment and Genetics Across Generations
The origin of idiopathic diseases is still poorly understood. The latent early-life associated regulation (LEARn) model unites environmental exposures and gene expression while providing a mechanistic underpinning for later-occurring disorders. We propose that this process can occur across generations via transgenerational LEARn (tLEARn). In tLEARn, each person is a ‘unit’ accumulating preclinical or subclinical ‘hits’ as in the original LEARn model. These changes can then be epigenomically passed along to offspring. Transgenerational accumulation of ‘hits’ determines a sporadic disease state. Few significant transgenerational hits would accompany conception or gestation of most people, but these may suffice to ‘prime’ someone to respond to later-life hits. Hits need not produce symptoms or microphenotypes to have a transgenerational effect. Testing tLEARn requires longitudinal approaches. A recently proposed longitudinal epigenome/envirome-wide association study would unite genetic sequence, epigenomic m...
- 1 July 2014
- Published by Wiley in Alzheimer's & Dementia
- Vol. 10 (4S_Part_8)
P1‐066: TREATMENT WITH SP1 INHIBITING DRUGS MODULATES APP AND BACE1 LEVELS IN HUMAN CELLS: IMPLICATION IN TESTING A NOVEL TARGET FOR ALZHEIMER'S DISEASE
- 1 July 2014
- Published by Wiley in Alzheimer's & Dementia
- Vol. 10 (4S_Part_8)
P1‐066: TREATMENT WITH SP1 INHIBITING DRUGS MODULATES APP AND BACE1 LEVELS IN HUMAN CELLS: IMPLICATION IN TESTING A NOVEL TARGET FOR ALZHEIMER'S DISEASE